MorphoSys AG
21.7.2021 22:22:12 CEST | ACCESS Newswire | Press release
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
- Jean-Paul Kress, M.D., Chief Executive Officer
- Sung Lee, Chief Financial Officer
- Roland Wandeler, Ph.D., Chief Operating Officer
- Malte Peters, M.D., Chief Research & Development Officer
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):
Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#
Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.
About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Promotes Kevin Gee to Vice President of Pro Product Development - FLEX28.9.2026 14:25:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / September 28, 2026 / Chervon promotes Kevin Gee to Vice President of Pro Product Development - FLEX, effective Monday, September 28, 2026, reporting to CEO Joe Galli. Kevin Gee joined Chervon after a 15-year international career in the Milwaukee Pro Power Tool business. He started his career at TTI in 2011 as a Field Sales Store Representative in Toronto, Ontario. He moved through several Milwaukee marketing positions in Canada and was then promoted to a marketing position with Milwaukee based in Hong Kong in 2013. He then rose to the position of Group Marketing Manager in Milwaukee Asia in 2016. In 2017, Kevin was moved to Milwaukee U.S.A. and advanced through a series of Milwaukee product management positions from 2017 to 2023. His final position was Director of Product Management for Milwaukee Pro Tools from 2021 to 2023. Most recently, Kevin held the position of Chief Revenue and Marketing Officer for Guardian Safety Equipment before joining Cherv
Chervon Names Trevor Bithrey Vice President Pro End User Marketing and Research - Canada28.9.2026 14:25:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / September 28, 2026 / Trevor Bithrey joins Chervon as Vice President, Pro End User Marketing and Research - Canada, effective Monday, September 28, reporting to CEO Joe Galli. Bithrey joins Chervon with over 25 years of professional power tools experience. He has excelled in his increasingly responsible positions in building both the DeWalt Canada business and the Milwaukee Canada business. He brings an impressive and diverse skillset in account management, end user marketing, aftersales service and end user research. He also has experience building and leading exceptional teams in Canada. Bithrey will also be part of the newly formed Chervon Global End User Research and Jobsite Marketing team, reporting directly to CEO Joe Galli. Bithrey's career started at DeWalt Canada where he held a series of sales and product management positions from 2000 to 2007. He then moved to Milwaukee Canada from 2007 until 2023 where he advanced through key leadership rol
Fermi Selects NAES to Operate and Maintain Its Natural Gas Turbine Fleet28.9.2026 13:00:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / September 28, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today an operations and maintenance (O&M) agreement with NAES Corporation ("NAES"), the largest independent operator of power plants in the United States. Under the agreement, NAES will run and maintain Fermi's natural gas turbine fleet at its Project Matador private-power campus in Carson County, Texas. "This agreement puts a proven and experienced operator in place that has been running power plants for more than 45 years," said Lee McIntire, Fermi Chief Executive Officer. "Our first customer is signed, our turbines are secured, and our EPC partners are on board. Now, with NAES, we're adding an operating partner with operations and maintenance depth, skilled crews, and proven management systems before the first natural-gas generation units come online. That protects uptime for the customers who are counting on us for quality and rel
Camino Receives Environmental Approval for Significant Exploration Expansion at the Costa de Cobre Copper Project in Peru28.9.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / September 28, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that its Peruvian subsidiary, a 65/35 joint venture between Camino and Nittetsu Mining Co., Ltd. ("Nittetsu"), has received approval from Peru's Ministry of Energy and Mines ("MINEM") for the Second Modification of the Semi-Detailed Environmental Impact Assessment ("Second MEIA-sd") for its Costa de Cobre Project (formerly known and referred to in the permit as Los Chapitos), along the coastline in southern Peru. The approval represents a major milestone for Costa de Cobre, increasing the effective exploration area by approximately 94%, from 6,012.50 hectares to 11,671.90 hectares, and expanding the environmental framework to support a total of 280 drill platforms and up to 611,840 metres of drilling capacity, covering major portions of the three copper fault trends crossing Camino's claims: Diva trend; La Estancia trend; and the
Case IQ Launches Quantum Approvals & Disclosures So Compliance Teams Find Risk Earlier28.9.2026 10:00:00 CEST | Press release
LONDON, GB / ACCESS Newswire / September 28, 2026 / Case IQ, a leading provider of compliance and risk management solutions, today announced the launch of Quantum Approvals & Disclosures, a native AI-powered solution designed to help organisations identify risk earlier, reduce manual effort, and make more consistent, defensible compliance decisions. In addition to the embedded governed AI capabilities that support employees and compliance reviewers, the solution launches with two ready-to-use AI agents, Submission Support and Risk Spotlight. Employees receive intelligent guidance that helps them submit more complete and accurate information, while compliance teams gain the context needed to prioritise higher-risk activity and proactively engage before potential issues escalate. The solution supports complex approval and disclosure programmes spanning conflicts of interest, gifts and hospitality, donations and sponsorships, and other risk areas. By bringing submissions, reviews, decisio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom